Results 71 to 80 of about 29,193 (227)

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Secondary Hyperparathyroidism as a Palpable Intrathyroid Parathyroid Gland in a Patient with Hypophosphatemic Osteomalacia

open access: yes, 2009
Secondary hyperparathyroidism is sometimes seen in patients with hypophosphatemic osteomalacia after long-term oral phosphate therapy. Parathyroidectomy is sometimes needed for the correction of hypercalcemia in these patients, and is rarely performed in
蘇登煌;廖國盟;張英俊;蔡克嵩   +1 more
core  

LACK OF RELATION BETWEEN SERUM PARATHYROID HORMONE LEVELS AND ERYTHROCYTE OSMOTIC FRAGILITY IN PEDIATRIC PATIENTS ON PERITONEAL DIALYSIS

open access: yesEurasian Journal of Medicine, 2019
Parathyroid hormone (PTH) has been shown to enhance erythrocyte osmotic fragility and has been incriminated as a factor in the anemia seen in patients with chronic renal failure and secondary hyperparathyroidism.
Celalettin Koşan, Lale Sever
doaj  

Vitamin D Pretreatment to Prevent the Risk of Postoperative Hypocalcemic Complications After Parathyroidectomy in Primary Hyperparathyroidism: A Systematic Review and Meta‐Analysis

open access: yesHead &Neck, Volume 48, Issue 7, Page 1865-1875, July 2026.
ABSTRACT Background Parathyroidectomy is the treatment for primary hyperparathyroidism, yet postoperative hypocalcemia and hungry bone syndrome remain common. Vitamin D deficiency has been suggested as a modifiable risk factor, but evidence supporting preoperative supplementation is inconsistent.
Matthew Gynn   +2 more
wiley   +1 more source

Multiple brown tumors in a patient with nutritional secondary hyperparathyroidism.

open access: yes, 1989
For years, brown tumors have been considered to be a characteristic of primary hyperparathyroidism. However, since 1963 several reports indicate that the incidence of brown tumors in patients with renal secondary hyperparathyroidism to be 1.5%-1.7%.
Mergenthaler, H.G.   +4 more
core   +1 more source

Primary and Secondary Hyperparathyroidism in Patients with Primary Aldosteronism - Findings From the German Conn's Registry

open access: yes, 2020
CONTEXT Recent studies support a bidirectional interaction between aldosterone and parathyroid hormone (PTH), possibly increasing the individual cardiovascular risk.
Quinkler, Marcus   +10 more
core   +1 more source

Periodontitis and Periodontal Conditions in Systemically Healthy Children and Adolescents

open access: yesJournal of Clinical Periodontology, Volume 53, Issue 7, Page 1100-1198, July 2026.
ABSTRACT Objective To answer the PICoS question ‘in systemically healthy children and adolescents (Population), what are the main features of periodontitis, necrotising periodontal diseases (NPD) and other periodontal conditions (periodontal abscesses, endo‐periodontal lesions, traumatic occlusal forces, prosthesis‐ and tooth‐related factors ...
Inbar Eshkol‐Yogev   +5 more
wiley   +1 more source

Comparison of scintigraphy and ultrasound imaging in patients with primary, secondary and tertiary hyperparathyroidism – own experience

open access: yes, 2017
Background: The imaging techniques most commonly used in the diagnosis of hyperparathyroidisms are ultrasound and scintigraphy. The diagnostic algorithms vary, depending mainly on the population, and experience of physicians.
Katarzyna Fronczewska-Wieniawska   +15 more
core   +1 more source

Mandibular Osteitis Fibrosa Cystica as First Sign of Vitamin D Deficiency

open access: yesCase Reports in Dentistry, 2018
Introduction. Brown tumors of hyperparathyroidism are locally destructive bone lesions. They are the late clinical consequence of the disease. They can occur in primary, secondary, and rarely tertiary forms.
Nour Mellouli   +5 more
doaj   +1 more source

Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism

open access: yesTherapeutic Apheresis and Dialysis, Volume 30, Issue 3, Page 309-322, June 2026.
ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy